Hyperprolactinemia with aripiprazole

Understanding the paradox

Gayatri Saraf, Rishikesh V. Behere, Ganesan Venkatasubramanian, Naren P. Rao, Shivarama Varambally, B. N. Gangadhar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

Original languageEnglish
JournalAmerican Journal of Therapeutics
Volume21
Issue number3
DOIs
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Hyperprolactinemia
Prolactin
Antipsychotic Agents
Dopamine
Aripiprazole
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Saraf, G., Behere, R. V., Venkatasubramanian, G., Rao, N. P., Varambally, S., & Gangadhar, B. N. (2014). Hyperprolactinemia with aripiprazole: Understanding the paradox. American Journal of Therapeutics, 21(3). https://doi.org/10.1097/MJT.0b013e3182456de7
Saraf, Gayatri ; Behere, Rishikesh V. ; Venkatasubramanian, Ganesan ; Rao, Naren P. ; Varambally, Shivarama ; Gangadhar, B. N. / Hyperprolactinemia with aripiprazole : Understanding the paradox. In: American Journal of Therapeutics. 2014 ; Vol. 21, No. 3.
@article{feaf2d31eeee4c9ea119c9db44e59572,
title = "Hyperprolactinemia with aripiprazole: Understanding the paradox",
abstract = "Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.",
author = "Gayatri Saraf and Behere, {Rishikesh V.} and Ganesan Venkatasubramanian and Rao, {Naren P.} and Shivarama Varambally and Gangadhar, {B. N.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MJT.0b013e3182456de7",
language = "English",
volume = "21",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Saraf, G, Behere, RV, Venkatasubramanian, G, Rao, NP, Varambally, S & Gangadhar, BN 2014, 'Hyperprolactinemia with aripiprazole: Understanding the paradox', American Journal of Therapeutics, vol. 21, no. 3. https://doi.org/10.1097/MJT.0b013e3182456de7

Hyperprolactinemia with aripiprazole : Understanding the paradox. / Saraf, Gayatri; Behere, Rishikesh V.; Venkatasubramanian, Ganesan; Rao, Naren P.; Varambally, Shivarama; Gangadhar, B. N.

In: American Journal of Therapeutics, Vol. 21, No. 3, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hyperprolactinemia with aripiprazole

T2 - Understanding the paradox

AU - Saraf, Gayatri

AU - Behere, Rishikesh V.

AU - Venkatasubramanian, Ganesan

AU - Rao, Naren P.

AU - Varambally, Shivarama

AU - Gangadhar, B. N.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

AB - Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=84900790133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900790133&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3182456de7

DO - 10.1097/MJT.0b013e3182456de7

M3 - Article

VL - 21

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -

Saraf G, Behere RV, Venkatasubramanian G, Rao NP, Varambally S, Gangadhar BN. Hyperprolactinemia with aripiprazole: Understanding the paradox. American Journal of Therapeutics. 2014 Jan 1;21(3). https://doi.org/10.1097/MJT.0b013e3182456de7